

**F. Submission and Deadline***Application*

Submit the original and five copies of PHS-398 (OMB Number 0925-0001) (adhere to the instructions on the Errata Instruction Sheet for PHS-398). Forms are available at the following Internet address: <http://www.cdc.gov/...Forms>, or in the application kit.

On or before May 30, 2001, submit the application to the Grants Management Specialist identified in the "Where to Obtain Additional Information" section of this announcement.

**G. Evaluation Criteria**

The application will be evaluated individually against the following criteria by an independent review group appointed by CDC.

*1. Plan (10 points)*

Extent to which the applicant presents a detailed operational plan for continuing and conducting the project, and which clearly and appropriately addresses all Recipient Activities.

*2. Objectives (15 points)*

Extent to which the applicant describes specific objectives for the continuation of the project which are consistent with the purpose of this program, and which are measurable and time-phased.

*3. Methods (30 points)*

Extent to which the applicant clearly identifies specific assigned responsibilities for all key professional personnel. Extent to which the plan clearly describes the applicant's technical approach/methods for conducting the proposed study and extent to which the plan is adequate to accomplish the purpose. Extent to which the applicant describes specific study protocols, or plans for the continuation of study protocols that are appropriate for the purpose of the project. The degree to which the applicant has met the CDC Policy requirements regarding the inclusion of women, ethnic, and racial groups in the proposed research. This includes (1) the proposed plan for the inclusion of both sexes, and racial, and ethnic minorities, (2) the proposed justification when representation is limited or absent, (3) a statement as to whether the design of the study is adequate to measure differences when warranted, and (4) a statement as to whether the plans for recruitment and outreach for study participants include the process of establishing partnerships with community(ies) and recognition of mutual benefits.

*4. Capacity (30 points)*

Extent to which the applicant can document past experience and achievement in successfully completing the types of recipient activities necessary for achieving the purpose of this project, and the extent to which the applicant demonstrates the ability to successfully collaborate with many blood banks in the United States on blood safety issues, such as those related to CJD.

*5. Evaluation (15 points)*

Extent to which the applicant provides a detailed and adequate plan for evaluating study results and for evaluating progress toward achieving the purpose of the project.

*6. Budget (not scored)*

Extent to which the line-item budget is detailed, clearly justified, and consistent with the purpose and objectives of this program.

*7. Human Subjects (not scored)*

Does the application adequately address the requirements of Title 45 CFS Part 46 for the protection of human subjects?

**H. Other Requirements***Technical Reporting Requirements*

Provide CDC with an original plus two copies of the following:

1. Progress reports (annual);
2. Financial status report, no more than 90 days after the end of the budget period; and
3. Final financial and performance reports, no more than 90 days after the end of the project period.

Send all reports to the Grants Management Specialist identified in the "Where to Obtain Additional Information" section of this announcement.

The following additional requirements are applicable to this program. For a complete description of each, see Attachment I in the application kit.

- AR-1 Human Subjects Requirements
- AR-2 Requirements for Inclusion of Women and Racial and Ethnic Minorities in Research
- AR-9 Paperwork Reduction Act Requirements
- AR-10 Smoke-Free Workplace Requirements
- AR-11 Healthy People 2010
- AR-12 Lobbying Restrictions
- AR-15 Proof of Non-Profit Status

**I. Authority and Catalog of Federal Domestic Assistance Number**

This program is authorized under section 301(a) and 317(k)(2) of the

Public Health Service Act, [42 U.S.C. Sections 241(a) and 247b(k)(2)], as amended. The Catalog of Federal Domestic Assistance number is 93.283.

**J. Where to Obtain Additional Information**

This and other CDC announcements can be found on the CDC home page Internet address <http://www.cdc.gov>. Click on "Funding" then "Grants and Cooperative Agreements."

To obtain additional information, contact: Andrea Wooddall, Grants Management Specialist, Grants Management Branch, Procurement and Grants Office, Centers for Disease Control and Prevention, Room 3000, 2920 Brandywine Road, Atlanta, GA 30341-4146, Telephone number (770) 488-2749, Email address [ayw3@cdc.gov](mailto:ayw3@cdc.gov).

For program technical assistance, contact: Dr. Larry Schonberger, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road, NE., Atlanta, GA 30333, Telephone number 404-639-3091, Email address [lbs1@cdc.gov](mailto:lbs1@cdc.gov).

Dated: April 4, 2001.

**John L. Williams,**

*Director, Procurement and Grants Office, Centers for Disease Control and Prevention (CDC).*

[FR Doc. 01-8745 Filed 4-9-01; 8:45 am]

BILLING CODE 4163-18-P

**DEPARTMENT OF HEALTH AND HUMAN SERVICES****Administration for Children and Families****Proposed Information Collection Activity; Comment Request**

*Title:* Low Income Home Energy Assistance Program (LIHEAP) Grantee Survey.

*OMB No.:* 0970-0076.

*Description:* The LIHEAP Grantee Survey is an annual data collection activity, which is sent to the 50 States and the District of Columbia grantees administering the Low Income Home Energy Assistance Program (LIHEAP). The survey requests estimates on sources and uses of funds under LIHEAP—preliminary estimates for the current fiscal year and final estimates for the previous fiscal year. We are proposing changes in the collection of data using the Grantee Survey, generally to reduce the burden on grantees. In addition, the annual submission of the Grantee Survey will be changed from

voluntary to mandatory. The change from voluntary to mandatory is necessary to increase the reliability of the data and to make it available on a more timely basis. Section 2605(b)(14) of the Low Income Home Energy Assistance Act, as amended, requires grantees to provide assurance that they will cooperate with the Secretary with respect to data collecting and reporting. This is one of 16 assurances a State's

governor or someone specifically designated by the governor, makes as part of each year's LIHEAP application. To be in full compliance with section 2605(b)(14), grantees must return the completed survey by the due date. The preliminary estimates collected by the Grantee Survey for the current fiscal year are needed to provide the Administration and Congress with fiscal and case load estimates in time for

hearings about LIHEAP appropriations and program performance. Final estimates for the previous fiscal year will be included in the Department's annual LIHEAP Report to Congress and will be posted on the Department's LIHEAP web site for access by grantees and other interested parties. Respondents: 50 States and the District of Columbia.

**Annual Burden Estimates**

| Instrument                                 | Number of respondents | Number of responses per respondent | Average burden hours per response | Total burden hours |
|--|-----------------------|------------------------------------|-----------------------------------|--------------------|
| Survey .....                               | 51                    | 1                                  | 3.5                               | 178.5              |
| Estimated Total Annual Burden Hours: ..... |                       |                                    |                                   | 178.5              |

In compliance with the requirements of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Administration for Children and Families is soliciting public comment on the specific aspects of the information collection described above. Copies of the proposed collection of information can be obtained and comments may be forwarded by writing to the Administration for Children and Families, Office of Information Services, 370 L'Enfant Promenade, SW., Washington, DC 20447, Attn: ACF Reports Clearance Officer. All requests should be identified by the title of the information collection.

The Department specifically requests comments on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the proposed collection of information; (c) the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication.

Dated: April 4, 2001.

**Bob Sargis,**  
*Reports Clearance Officer.*  
 [FR Doc. 01-8765 Filed 4-9-01; 8:45 am]  
**BILLING CODE 4184-01-M**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Food and Drug Administration**

[Docket No. 98N-0787]

**Parke-Davis Pharmaceutical Research et al.; Withdrawal of Approval of 14 New Drug Applications and 13 Abbreviated New Drug Applications; Correction**

**AGENCY:** Food and Drug Administration, HHS.  
**ACTION:** Notice; correction.

**SUMMARY:** The Food and Drug Administration (FDA) is correcting a notice that appeared in the **Federal Register** of September 25, 1998 (63 FR 51359). The document announced the withdrawal of approval of 14 new drug applications and 13 abbreviated new drug applications (ANDAs). The document inadvertently withdrew approval of ANDA 80-025 for Sulf-10 (sulfacetamide sodium ophthalmic solution, USP) 10% held by Ciba Vision, 11460 Johns Creek Pkwy., Duluth, GA 30097-1556. FDA confirms that approval of ANDA 80-025 is still in effect.

**EFFECTIVE DATE:** September 25, 1998.  
**FOR FURTHER INFORMATION CONTACT:** Olivia A. Pritzlaff, Center for Drug Evaluation and Research (HFD-7), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-594-2041.

In FR Doc. 98-25713 appearing on page 51359 in the issue of Friday, September 25, 1998, the following correction is made: On page 51360, in the table, the entry for ANDA 80-025 is removed.

Dated: March 26, 2001.

**Janet Woodcock,**  
*Director, Center for Drug Evaluation and Research.*

[FR Doc. 01-8718 Filed 4-9-01; 8:45 am]  
**BILLING CODE 4160-01-S**

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**Health Care Financing Administration**

[Document Identifier: HCFA-R-0209 and HCFA-R-0245]

**Agency Information Collection Activities: Submission for OMB Review; Comment Request**

**AGENCY:** Health Care Financing Administration, DHHS.

In compliance with the requirement of section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Health Care Financing Administration (HCFA), Department of Health and Human Services, is publishing the following summary of proposed collections for public comment. Interested persons are invited to send comments regarding this burden estimate or any other aspect of this collection of information, including any of the following subjects: (1) The necessity and utility of the proposed information collection for the proper performance of the agency's functions; (2) the accuracy of the estimated burden; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) the use of automated collection techniques or other forms of information technology to minimize the information collection burden.

1. *Type of Information Collection Request:* Extension of a currently